Document is current
Any future updates will be listed below
-
Authors
Roth, Thomas
-
Funding
Funding for this research was provided by:
Avadel Pharmaceuticals
- License Information
-
More Information
Article History
Accepted: 27 November 2024
First Online: 20 March 2025
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Avadel Pharmaceuticals (Chesterfield, MO, USA). Preparation of this manuscript was funded by Avadel Pharmaceuticals. Avadel Pharmaceuticals was involved in the writing of the manuscript and in the decision to submit for publication. Open access publication and publication costs were funded by Avadel Pharmaceuticals.
: Thomas Roth is a consultant for Avadel Pharmaceuticals, Eisai, Idorsia, Jazz Pharmaceuticals, Merck & Co., Orexo, and Takeda Pharmaceutical Co.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Thomas Roth contributed to the conceptualization and refining of the review, analysis and interpretation, and writing of the original draft, as well as reviewing and editing the manuscript.
